Spelling suggestions: "subject:"1protein p53"" "subject:"2protein p53""
81 |
Multiple modes of MDMX regulation affect p53 activationGilkes, Daniele M. January 2008 (has links)
Dissertation (Ph.D.)--University of South Florida, 2008. / Title from PDF of title page. Document formatted into pages; contains 197 pages. Includes vita. Includes bibliographical references.
|
82 |
Mechanisms of P53-mediated apoptosisHarms, Kelly Lynn. January 2007 (has links) (PDF)
Thesis (Ph.D.)--University of Alabama at Birmingham, 2007. / Title from first page of PDF file (viewed on June 24, 2009). Includes bibliographical references.
|
83 |
Novel immunomodulatory oligonucleotides for cancer therapyRayburn, Elizabeth R. January 2007 (has links) (PDF)
Thesis (Ph.D.)--University of Alabama at Birmingham, 2007. / Title from first page of PDF file (viewed on June 26, 2009). Includes bibliographical references.
|
84 |
The role of DEC1 in P53-dependent cellular senescenceQian, Yingjuan, January 2008 (has links) (PDF)
Thesis (Ph.D.)--University of Alabama at Birmingham, 2008. / Title from first page of PDF file (viewed on June 26, 2009). Includes bibliographical references.
|
85 |
Structural and biochemical characterization of proteins involved in cancerGhosh, Madhumita. January 2005 (has links) (PDF)
München, Techn. University, Diss., 2005.
|
86 |
Perturbation and Modulation of Microtubule Cytoskeletal Elements in Response to the Potentially Oncogenic Molecules, Survivin and P53, and Cytokinesis: A DissertationRosa, Jack 17 July 2006 (has links)
A complex network of protein filaments collectively known as the cytoskeleton carries out several crucial cellular processes. These functions include, but are not limited to, motility, cell shape, mitosis and organelle trafficking. The cytoskeleton is also highly responsive, allowing the cell to alter its shape in response to its immediate needs and environment. One of the major components of the cytoskeleton is the microtubule network. To refer to the array of micro tubules in the cell as a skeleton is a misnomer. Microtubules, by virtue of their structure and nature, are highly dynamic, continuously growing and shrinking. They also bind a variety of accessory molecules that aid in regulating and directing their dynamic activity. In this way they provide a structural basis for integral cell functions that require rapid assembly and disassembly. In some cases, perturbations of the microtubule network results in structural anomalies that lead to undesirable outcomes for the cell, namely chromosomal missegregation events and instability. The accumulation of these events may induce aneuploidy, which has been a fundamental component of tumorigenesis. This dissertation examines the role of the microtubule cytoskeleton within three distinct contexts. The first chapter investigates the association of the anti-apoptotic protein survivin with the microtubule network and its potential impact upon the cell from interphase to cytokinesis. The second chapter of this dissertation explores a little-studied, microtubule-dense organelle, referred to as the midbody, and the highly orchestrated events that take place within it during cytokinesis. The third and final chapter describes a unique experimental condition that may further our understanding of the interaction between the tumor suppressor p53 and the centrosome in cell cycle regulation and tumorigenesis.
|
87 |
Dissecting the Mechanism for the Selective Induction of Apoptosis in Transformed Cells by CAV Apoptin: a DissertationHeilman, Destin W. 01 March 2006 (has links)
Most existing chemotherapeutics lack adequate specificity for transformed cells and therefore have high rates of collateral damage to normal tissue. Moreover, such therapies often depend on p53 to induce cell death and are ineffective on the large number of human cancers that have lost p53 function. The discovery of novel p53-independent cancer therapies is therefore of significant interest. The Chicken Anemia Virus protein Apoptin selectively induces apoptosis in transformed cells in a p53-independent manner while leaving normal primary cells unaffected. This selectivity is thought to be largely due to cell type-specific localization: in primary cells Apoptin is cytoplasmic, whereas in transformed cells the protein localizes to the nucleus. The basis for this cell type-specific localization remains to be determined. In this study, Apoptin is revealed to be a nucleo-cytoplasmic shuttling protein whose localization is mediated by an N-terminal nuclear export signal (NES) and a C-terminal nuclear localization signal (NLS). Both signals are required for cell type-specific localization, as Apoptin fragments containing either the NES or NLS fail to localize differently between transformed and primary cells. Significantly, cell type-specific localization can be rescued in trans by co-expression of the two separate fragments, which are able to interact through an Apoptin multimerization domain. Interestingly, this multimerization domain overlaps with the NES suggesting that these two activities may be functionally coupled in cytoplasmic retention in primary cell types. Factors present in transformed cells induce localization of Apoptin to the nucleus where a biochemically distinct, more soluble form of the protein exists.
Using affinity-purification and mass spectroscopy it was found that, specifically in transformed cells, Apoptin is associated with APC1, a subunit of the anaphase-promoting complex/cyclosome (APC/C). The APC/C is required to establish a mitotic cell-cycle checkpoint, and its inhibition results in G2/M arrest and apoptosis. Expression of wild type Apoptin in transformed cells inhibits APC/C function and induces G2/M arrest and apoptosis, whereas Apoptin mutants that are unable to associate with APC1 have no effect. In p53 null cells, ablation of APC1 by RNA interference induces a G2/M arrest and apoptosis analogous to that observed following Apoptin expression. Furthermore, Apoptin was found to induce the formation of PML bodies and to recruit APC/C subunits to these nuclear structures suggesting a mechanism involving sequestration and subsequent inhibition of the APC/C.
Thus, the results of this study clarify Apoptin cell type-specific localization behavior and explain the ability of Apoptin to induce apoptosis in transformed cells in the absence of p53. This study advances a newly emerging field of viral mechanisms of apoptosis involving G2/M arrest and APC/C modulation. The resultant p53-independent apoptosis suggests that the APC/C may be an attractive target for the development of anti-cancer drugs.
|
88 |
Análise da densidade da microvasculatura e da expressão do gene p53 no adenocarcinoma pancreático / Evaluation of microvessel density and p53 in pancreatic adenocarcinomaRicardo Jureidini 01 October 2009 (has links)
O adenocarcinoma pancreático é a neoplasia maligna mais comum do pâncreas. A alta taxa de mortalidade deve-se ao diagnóstico tardio e a alta agressividade do tumor. Freqüentemente observam-se indivíduos com neoplasias de mesmo estadio apresentarem sobrevivência diferente. Isso demonstra a necessidade de incluir mais variáveis na caracterização da doença. O processo de angiogênese é essencial para o crescimento tanto do tumor primário, quanto para o metastático. A medida da densidade intratumoral da microvasculatura (DMV) por imunoistoquímica é o método mais confiável para medir a atividade angiogênica tumoral. A perda da função do gene p53 influencia a resposta à quimio e à radioterapia além de regular a angiogênese. A sobrevivência está inversamente relacionada à positividade do p53 e à DMV em neoplasias de mama, pulmão, ovários, estômago, cólon, laringe e bexiga. No adenocarcinoma pancreático os resultados são controversos. Idealizou-se essa pesquisa retrospectiva analisando-se dados clínicos e os resultados de estudos imunoistoquímicos obtidos de adenocarcinomas de pâncreas ressecados com intenção curativa. Analisou-se dados clínicos, patológicos, re-estadiamento e resultados da DMV e da expressão do gene p53 em 49 pacientes. A densidade média de microvasos foi de 46,2 vasos/mm2 sendo que esse valor foi utilizado para dividir os pacientes em grupos de baixa ou alta densidade de vasos. A coloração para p53 nuclear foi considerada positiva em 20 de 49 pacientes (40,8%). A DMV foi significativamente maior nos pacientes com tumores maiores que 3,0 cm e nos pacientes com ressecções incompletas. A expressão do gene p53 e a DMV, não foram fatores preditivos da sobrevivência pós-operatória. Não foi possível verificar relação entre a expressão do gene p53 e a densidade da microvasculatura tumoral / The prognostic significance of microvessel density and the p53 expression was evaluated. Between 1993 and 2006, 49 patients with pancreatic adenocarcinoma were ressected with curative intention. Specimens were stained immunohistochemically with antibodies anti- p53 anti-CD34. Microvessel density (MVD) was assessed scanning ten areas of the tumoral section and counted at a high power in an adequate area. The MVD ranged from 21,2 to 54,2 vessels/mm2 (mean 46,2 vessels/mm2). Specific nuclear staining for p53 was determined positive in 20 patients (40,8%). The overall median survival was 24,1 months after resection and there was no difference in survival rates according to the MVD and p53 positivity. There was also no relation between the MVD and p53 expression. MVD and p53 expression could not predict survival in these patients with pancreatic adenocarcinoma. There was no correlation with p53 expression and intratumoral microvessel density. High MVD was associated with tumor size grater than 3,0 cm and positive margins
|
89 |
Remediação das vias p53/Arf e interferon-beta como uma estratégia de imunoterapia do câncer: uma abordagem de transferência gênica / Remediation of the p53/Arf and Interferon-beta pathways as a cancer immunotherapy strategy: a gene transfer approachRuan Felipe Vieira Medrano 08 January 2018 (has links)
As células tumorais prosperam como consequência da capacidade de resistir aos mecanismos de morte celular e de evasão da vigilância imunológica. Nós propomos que, em cânceres que possuem o supressor de tumor p53 selvagem, a remediação de ambas dessas defesas pode ser promovida pela transferência genica combinada de vetores adenovirais portadores dos transgenes de p19Arf (proteína supressora de tumor, parceira funcional de p53) e de interferon-beta (IFNbeta, citocina imunomoduladora). De fato, em resultados anteriores, notamos que a transdução combinada (p19Arf/IFNbeta), mas não os tratamentos individuais, em células de melanoma murino B16F10 resulta em aumento massivo de morte celular. Porém a capacidade destas células em processo de morte de desencadear imunidade antitumoral não foi analisada. Nesta tese e em estudos complementares, buscamos investigar os mecanismos moleculares de morte celular envolvidos na resposta imune estimulada por p19Arf/IFNbeta e explorar sua aplicação como imunoterapia do câncer. Inicialmente, em modelo de vacinação profilática, revelamos que o tratamento combinado em células B16F10 promove a expressão de IL-15, ULBP1, dos receptores de morte FAS/APO1 e KILLER/DR5, assim como uma resposta de células natural killer que rejeitam estas células tratadas quando inoculadas em camundongos imunocompetentes singênicos. Após desafio tumoral no flanco oposto, a progressão desses tumores foi fortemente reduzida devido ao engajamento de linfócitos T CD4+ e CD8+, que apresentaram produção aumentada das citocinas IFN-? e TNF-alfa e medeiam proteção antitumoral de longo prazo. Em seguida, explorando um contexto de imunização diferente, a transferência de gênica in situ foi realizada em carcinoma heterotópico de pulmão e exibiu proteção significativa contra um desafio tumoral secundário, apenas quando o tumor primário foi tratado com p19Arf/IFNbeta. Análise de transcriptoma destes tumores indicou uma assinatura quimiotáxica de neutrófilos e linfócitos T CD8+ através das quimiocinas CCL3, CXCL3 e da IL-1beta. Em apoio destas observações, análises mecanicistas in vitro revelaram que células tratadas com p19Arf/IFNbeta ativam programas apoptóticos de p53 e antivirais de IFNbeta, enquanto sucumbem a um processo de morte por necroptose que também libera moléculas de morte celular imunogênica (MCI), calreticulina, ATP e HMGB1. No entanto, procurando potencializar ainda mais o benefício terapêutico dos nossos vetores, exploramos sua associação com o quimioterápico imunogênico doxorrubicina (Dox), que também é indutor de MCI. E nesta associação, percebemos que a Dox aumenta não apenas os níveis de morte celular, mas também a imunogenicidade das células tratadas, proporcionando em um modelo de vacina terapêutica, um controle tumoral superior em camundongos que já portavam antes da vacinação tumores B16F10 ou MCA205. Além disso, a associação in situ destas terapias restaurou a eficácia de uma dose sub-terapêutica de Dox, que em contraste com sua dose terapêutica, não prejudica a função cardíaca. Finalmente, também exploramos a associação com o bloqueio dos pontos de controle imunológicos PD-1 ou CTLA-4, que no modelo de vacina terapêutica, sua associação induziu maior rejeição completa de tumores B16F10. Em conclusão, aqui apresentamos evidências sobre a capacidade da combinação p19Arf/IFNbeta de induzir morte celular e estimulação imunológica. E ressaltamos seu potencial como uma estratégia de imunoterapia do câncer / Cancer cells thrive as a consequence of resisting cell death mechanisms and escaping from immune surveillance. We propose that, in cancers that harbor the wild-type tumor suppressor p53, remediation of both of these defenses can be achieved by harnessing the adenoviral vector mediated gene transfer of p19Arf (tumor suppressor protein, p53 functional partner) together with interferon-beta (IFNbeta, immunomodulatory cytokine). Indeed, in our initial observations, it was noticed that combined-transduction (p19Arf/IFNbeta), but not the individual treatments, of B16F10 mouse melanoma cells results in massive cell death levels. Yet, the capability of these dying cells to unleash antitumor immunity was not investigated. Here in this thesis and in complementary studies, we sought to investigate the molecular mechanisms of cell death involved in the p19Arf/IFNbeta immune stimulation and explore its potential as a mediator of cancer immunotherapy. First, in a prophylactic B16F10 vaccine model, we revealed that the dual treatment led to the up-regulation of IL-15, ULBP1, FAS/APO1 and KILLER/DR5 death receptors, plus a natural killer cell response that completely rejects treated cells when inoculated in syngeneic immunocompetent mice. Whereas, upon a contralateral tumor challenge, progression was strongly reduced by engaging both CD4+ and CD8+ T cells, which displayed augmented production of IFN-? and TNF-alpha cytokines and provided long term antitumor protection. Next, exploring different immunization context, in situ gene transfer in a heterotopic lung carcinoma exhibited significant protection against a secondary tumor challenge only when the primary tumor was treated with p19Arf/IFNbeta. Transcriptome analysis of these treated tumors indicated a chemotaxic signature of neutrophils and CD8+ T cells with the involvement of CCL3, CXCL3 chemokines and IL-1beta. Moreover, in support of this evidence, mechanistic in vitro studies revealed that p19Arf/IFNbeta treated cells reactivate p53 apoptotic and IFNbeta antiviral programs, while succumbing to a necroptosis cell death processes that also releases immunogenic cell death (ICD) molecules, calreticulin, ATP and HMGB1. Yet, aiming to potentiate therapeutic benefit of our vectors, we explored their association with doxorubicin (Dox) immunogenic chemotherapy, which is also an inducer of ICD. And in this setting, this association with Dox enhances not only cell death levels but also immunogenicity of treated cells, providing superior tumor control in a therapeutic vaccine model, where mice were already bearing B16F10 tumors or MCA205 sarcomas before vaccination. Moreover, associated use of these therapies in situ rescued efficacy of a sub-therapeutic dose of Dox, which in contrast to its therapeutic dose, does not impair cardiac function. Finally, we also evaluated the association with PD-1 or CTLA-4 checkpoint blockade immunotherapy, which in the therapeutic vaccine model induced full tumor rejection in a greater number of mice. In sum, here we provide compelling evidence for the ability of the p19Arf/IFNbeta combined gene transfer to promote cell death and immunogenic stimuli and underscored its potential to be applied as a cancer immunotherapy strategy
|
90 |
Estudo comparativo dos aspectos clínicos, morfológicos e moleculares da ceratose actínica e do carcinoma de células escamosas na pele da região ventral abdominal de caninos domésticos / Comparative study of the clinical, morphological and molecular aspects of actinic keratosis and squamous cell carcinoma in the skin of the abdominal ventral region of domestic caninesDanielle Almeida Zanini 12 June 2017 (has links)
Os tumores cutâneos e subcutâneos em cães representam um terço das neoplasias nessa espécie. O carcinoma de células escamosas (CCE) é uma neoplasia maligna com origem no epitélio estratificado escamoso da pele e de outras superfícies mucosas. A etiologia do CCE em cães não é bem definida, porém é descrito que a exposição aos raios solares é um importante fator para seu desenvolvimento. O CCE, frequentemente, é precedido pela ceratose actínica (CA). Este trabalho tem como objetivo comparar aspectos clínicos, morfológicos e moleculares da ceratose actínica e carcinoma de células escamosas da pele da região abdominal ventral de cães. Foram coletadas dez amostras de pele apresentando CCE e 9 amostras de pele apresentando CA da região abdominal ventral de caninos domésticos. As amostras foram fixadas em formol a 10%, e rotineiramente processadas para inclusão em parafina. Os cortes histológicos de 5?m foram submetidos à coloração de Hematoxilina e Eosina, para análise histopatológica, e às marcações, por imuno-histoquímica, de E-caderina, p53, Ciclo-oxigenase-2, pancitoqueratina AE1/AE2, vimentina, 5 metilcitosina e Ki67. As expressão de E-caderina, p53, ciclo-oxigenase-2, pancitoqueratina AE1/AE e vimentina foram avaliadas qualititivamente nas 9 amostras de CA e 10 amostras CCE, respectivamente. A metilação global do DNA e a proliferação celular (Ki67) foram quantificadas nos cortes histológicos de CA e CCE por meio da contagem de núcleos de células epiteliais marcados positiva ou negativamente. Os dados foram analisados por meio de testes uni e multivariados. Os cães machos da raça American PitBull Terrier de pelagem branca foram os mais acometidos pela CA e CCE, com média de idade de 8,1 e 8,4 anos, respectivamente. Não houve associação significativa na expressão de p53, COX-2 e vimentina na CA e CCE. Houve aumento no número de células com o núcleo marcado positivamente para Ki-67 e 5 metilcitosina em CCE comparado a CA. Observou-se, também, marcação heterogênea de Ecaderina em CCE. Constatou-se também diminuição na expressão de pancitoqueratina AE1/AE3 quando há invasão linfática e maior expressão de 5 metilcitosina em cães mais idosos, no CCE. Estes achados sugerem que há diferenças entre CA e CCE em relação aos parâmetros estudados, que condizem com a transformação maligna da afecção / Cutaneous and subcutaneous tumors in dogs account for a third of neoplasms in this species. Squamous cell carcinoma (SCC) is a malignant neoplasm that originates in the stratified squamous epithelium of the skin and other mucosal surfaces. The etiology of SCC is not well defined, however it is described that exposure to the sunlight is an important factor for its development. SCC is often preceded by actinic keratosis (AK). This work aims to compare clinical, morphological and molecular aspects of actinic keratosis and squamous cell carcinoma of the skin of the ventral abdominal region of dogs. Ten samples of SCC and 9 skin samples showing AK of the ventral abdominal region of domestic canines were collected. As samples were fixed in 10% formaldehyde, and routinely processed for inclusion in paraffin. Histological sections of 5?m were submitted to staining of Hematoxylin and Eosin for histopathological analysis, and to immunohistochemistry of E-cadherin, p53, Cyclooxygenase-2, pancytokeratin AE1/AE2, vimentin, 5 methylcytosine and Ki-67. The expression of E-cadherin, p53, cyclooxygenase-2, pancytokeratin AE1 / AE and vimentin were qualitatively evaluated in the 9 AK samples and 10 SCC samples, respectively. Overall DNA methylation and cell proliferation (Ki67) were quantified in the histological sections of AK and SCC by counting nuclei of positively or negatively labeled epithelial cells. The data were analyzed by means of uni and multivariate tests. Male dogs of the American PitBull Terrier breed were the most affected by AK and SCC, with an average age of 8.1 and 8.4 years, respectively. There was no significant association in the expression of p53, COX-2 and vimentin in CA and CCE. There was an increase in the number of cells with the nucleus positively labeled for Ki-67 and 5 methylcytosine in CCE compared to CA. There was also a heterogeneous labeling of Ecaderin in CCE. It was also observed a decrease in the expression of pancytokeratin AE1/AE3 when there is lymphatic invasion and greater expression of 5 methylcytosine in older dogs in the ECC. These findings suggest that there are differences between CA and SCC in relation to the studied parameters, which are consistent with the malignant transformation of the disease
|
Page generated in 0.0566 seconds